Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety Study of BHV-7000 in Refractory Focal Onset Epilepsy
NCT06443463Phase 2Enrolling by invitation
- Sponsor
- Biohaven Ltd.
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 2 trial of opakalim in Focal Onset Epilepsy, sponsored by Biohaven Ltd.. Started Jul 2024; status: enrolling by invitation.
02
Drugs
opakalim
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on NCT06443463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06443463.